Drugs / 177Lu girentuximab
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05663710 | Jun 2023 → Oct 2027 expected | clear cell renal carcinoma | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 177Lu girentuximab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05663710 ↗ |
| Route | Intravenous | “Given by IV (vein)” NCT05663710 ↗ |